Thomas Skjærlund Grønnebæk is a Clinical Trial Administrator at NMD Pharma. We asked him to share a few insights into what his role entails and what he enjoys most about his job. Find out more here: https://t.co/aeLG3Fi5Bm
#NMDPharma#neuromusculardisease@tgroennebaek
The cost of living with #CMT is substantial. The 3 million patients worldwide with the condition are unable to work and require physiotherapy and lifelong care.
At @NMDPharma, we are investigating the potential of our science for CMT.
Read more here: https://t.co/ROR4sS2GVk
I dag holder vi rundbord med rektorer, embedsmænd, eksperter og erhvervsliv om life science forskning sammen med @LifDK og @NovoNordiskLive. @BrianAMikkelsen byder velkommen. #dklifescience er vor alles guldæg, og her er offentlig og privat forskning helt afgørende. @DanskErhverv
Regeringens reformudspil vil hæve skatten på investeringer. Det er et meget ærgerligt initiativ. Vil på sigt komme til at give bagslag. Mangel på kapital er en af de største udfordringer for små og mindre virksomheder #rammevilkår#dkpol
Regeringens fokus på arbejdskraft er rigtigt, og der er flere gode takter i @regeringDK's udspil. Men finansieringen har flere tidsler og straffer bl.a. iværksætterne unødigt.
Læs flere kommentarer her ➡ https://t.co/Ny96d5ltq8
#dkbiz#dkpol
Yesterday Team NMD Pharma participated in the #dhlstafetten2021 in Aarhus. Great to have the muscles in full motion, and gather once again with colleagues after a virtual year🏃♂️😉🏃♀️
#NMDPharma#myotwitter#aarhusmotion
"GDPR-fortolkning" - gab, hvor kedeligt😴Men det r helt afgørende for vores sundhedsforskning. Når det ikke fungerer stopper forskningsprojekterne. Der r brug for national vejledning og kortere sagsbehandlingstider. Og det haster! https://t.co/bTd86jtcTb #sundpol
Congrats to our collaborators at @OhioState on their recent publication in BMJ Neurology Open. The study by Professors Elsheikh and @DaveArnoldLab highlights the high unmet medical need for novel treatments to address NMJ transmission defects. https://t.co/rkAKz9KK6h @bmj_company
Read about how ClC-1 inhibition can improve neuromuscular function in pharmacological models of compromised neuromuscular transmission - authoured by NMDPharma founders. Read the full paper in Acta Physiologica here: https://t.co/lk9kTG5tcC
#NMDPharma#ResearchPaper#Publication